RxDoctor Payments Data

Christopher Norwood, MD

Procedural Dermatology · New Britain, CTNPI 1174523583

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 27.8% of the total.

$1,130in general payments, 2019–2025

Across 46 payments — averaging $24.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$314
  • E.r. Squibb & Sons, L.L.C.$213
  • Galderma Laboratories, L.p.$141
  • Regeneron Healthcare Solutions, Inc.$96
  • LEO Pharma Inc.$72
  • Incyte Corporation$50
  • plus $243 from 9 others

What the payments were for

  • Food & beverage$1,11699%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few procedural dermatology providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$155,228
Medicare patients
450
Services billed
2,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast43$242,261
Dupixent PenDupilumab34$139,547
Dupixent SyringeDupilumab34$127,875
Cosentyx (2 Syringes)Secukinumab12$87,377
Fluorouracil93$5,807
Ketoconazole291$4,773
Ivermectin16$3,768
Clobetasol Propionate93$3,208
Metronidazole49$2,671
Doxycycline Monohydrate80$2,566
Tacrolimus21$1,474
Ciclopirox38$1,430
Triamcinolone Acetonide167$1,389
Calcipotriene13$1,345
Azelaic Acid20$1,265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisCosentyx (2 Syringes)$20$87,37712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few procedural dermatology providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other procedural dermatology in New Britain

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →